Tidewave Bio

https://lnkd.in/guAT-43z I’m pleased to share that Professor Alexander M.M. Eggermont, MD, PhD has joined Tidewave Bio as Head of our Clinical Advisory Board. Professor Eggermont is widely regarded as one of the leaders who helped shape modern cancer immunotherapy. His career includes serving as Director General of Gustave Roussy, President of EORTC and the European Academy of Cancer Sciences, and senior authorship of landmark immunotherapy trials published in NEJM and The Lancet. His work has directly influenced the evolution of adjuvant immunotherapy and global oncology strategy. As Tidewave advances its biopsy-native, gene-enhanced dendritic cell platform for solid tumors, Alexander’s experience in clinical trial design, translational immunology, and international oncology leadership will be instrumental in refining our development strategy and preparing for IND-enabling activities. Solid tumor immunotherapy continues to face biological and operational barriers. Our goal is to integrate full tumor antigen personalization with scalable immune activation and real-time clinical accessibility. Alexander’s perspective will be critical as we move from platform development toward clinical execution. Looking forward to the work ahead. #Immunotherapy #Oncology #CellTherapy #ClinicalDevelopment #Biotech #SolidTumors #TidewaveBio

Great experience collaborating with the JEAP team and deepening our understanding of the Japanese advanced therapy ecosystem and business landscape. Grateful for the insights and connections made throughout the program — and excited to showcase what we’ve built at Demo Day in Tokyo on February 20, 2026 (Fri)! Looking forward to continuing the dialogue with global partners and investors who are passionate about accelerating innovation in advanced therapies and scalable immunotherapy. https://lnkd.in/gEdUNspG #JEAP2025 #AdvancedTherapies #RegenerativeMedicine #TidewaveBio #TokyoDemoDay #Biotech

🌊 On the Concept of Convergence After 30+ years working across biologics, cell therapy, biomaterials, medical devices, and biosurgery, I’ve learned one thing: breakthroughs rarely come from a single field — they come from convergence. At Tidewave Bio, this principle drives everything we do. Our goal is bold — to make advanced cell therapy finally work for the 90% of cancer patients with solid tumors. That means combining potent biology, smart simple device engineering, and procedural innovation to deliver powerful therapies that are scalable, fast, and cost-effective. 👇 Read on to see why the tools to make this possible already exist — and how we’re bringing them together at Tidewave Bio. I’ve been using this term a lot lately — in presentations, on our website, in conversations — because convergence truly sits at the heart of Tidewave Bio’s innovation. At Tidewave Bio, convergence means more than just adding AI or digital tools to the mix. Our mission is to make advanced cell therapy finally work for the broader population of solid tumor patients — those who have been left behind by today’s personalized therapies. To do that, we need both: Potent biology — to overcome the inherent challenges of solid tumors. A reimagined business and delivery model — to make this therapy scalable, rapid, and cost-effective for real-world deployment. That’s why our approach blends cell therapy, device engineering, and procedural innovation. From tumor-tissue processing and real-time release testing to turnkey hospital workflows, every element is designed to collapse the gap between diagnosis and intervention — transforming patient care from complex to accessible. 💡 The exciting part is that the tools to make this possible already exist. The science, the devices, the workflows — they’re all here. The real challenge is to bring them together, align them under a common mission, and deliver. At Tidewave Bio, we’re building that convergence — uniting scientists, engineers, oncologists, surgeons, nurses and integrating technologies across disciplines to make a tangible impact for patients with limited treatment options. For our team, convergence isn’t just a concept — it’s our roadmap. #Convergence #CellTherapy #Immunotherapy #Oncology #BiotechInnovation #MedTech #DigitalHealth #ProceduralInnovation #TranslationalScience #FutureOfMedicine #TidewaveBio

https://lnkd.in/gYNgd7tH Even as some players pull back, investment in cell therapy innovation continues to grow — reaffirming both the scale of the opportunity and the life-changing potential these therapies hold for cancer patients. Kite’s recent $1.5B partnership with Pregene is a strong reminder that the field is far from saturated. Cell therapy is still in its early innings — and the next wave of innovation is about accessibility, scalability, and precision. At Tidewave Bio, we’re transforming the business model of cell therapy with a universal, off-the-shelf product that can be instantly personalized at the point of care using a patient’s own tumor biopsy. This innovation combines scalability and real-time personalization — overcoming today’s core limitations in treating solid tumors, including heterogeneity and immune evasion. One universal product, transformed into a patient-specific precision medicine at the point of care. A scalable, potent, and broadly accessible platform is an undeniable value proposition — for patients, clinicians, and investors alike. #CellTherapy #OncologyInnovation #PrecisionMedicine #Immunotherapy #Biotech #TidewaveBio

Tidewave Bio is proud to be part of #Biofuture2025! Our Chief Medical Officer, Michael Montgomery, MD, will join a panel discussing Next-Generation Innovation in Oncology, exploring how new approaches are reshaping the future of cancer care. Connect with Michael Montgomery, MD to learn more about how we’re changing the way solid tumor cancer is treated. #Biofuture2025 #Oncology #Innovation #CellTherapy #Immunotherapy #Biotech

Tidewave Bio is proud to be part of #Biofuture2025! Our Chief Medical Officer, Michael Montgomery, MD, will join a panel discussing Next-Generation Innovation in Oncology, exploring how new approaches are reshaping the future of cancer care. Connect with Michael Montgomery, MD to learn more about how we’re changing the way solid tumor cancer is treated. #Biofuture2025 #Oncology #Innovation #CellTherapy #Immunotherapy #Biotech

Tidewave Bio is kicking off the partnering season with the most relevant one #CellTherapy, and #GeneTherapy. Looking forward to productive partnering meetings next week #CGMesa25. Come and find Francois Binette for conversations on transformational IO therapy solution for solid tumors.